ST6GAL1 and prostate neoplasm: The data presented in this manuscript indicate that ST6GAL1-mediated aberrant sialylation could also be an important mediator of the acquired resistance of prostate tumours to enzalutamide therapy (which is a major clinical issue potentially affecting all men who develop CRPC [101].